Products Verdiperstat + Placebo
Verdiperstat + Placebo Phase 3 Completed 📈 Rising Jul 29, 2019 → Jun 30, 2022
About Verdiperstat + Placebo Verdiperstat + Placebo is a phase 3 stage product being developed by Biohaven for Multiple System Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT03952806. Target conditions include Multiple System Atrophy.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT03952806 Phase 3 Completed Jul 29, 2019 Jun 30, 2022 Multiple System Atrophy
Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1
Other Products from Biohaven